Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Moxalactam. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS1 | P23219 | 1/20 | 0.99 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.79 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.79 |
| ▸ | CMA1 | P23946 | 18/20 | 0.67 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Moxalactam SCHEMBL584454 | 1.00 | PTGS1 (0.99) | PTGS1HSD17B10TDP1CMA1 | |
| Moxalactam SCHEMBL951857 | 1.00 | PTGS1 (0.99) | PTGS1HSD17B10TDP1CMA1 | |
| Moxalactam SCHEMBL951858 | 1.00 | PTGS1 (0.99) | PTGS1HSD17B10TDP1CMA1 | |
| Moxalactam SCHEMBL9800360 | 0.99 | PTGS1 (0.97) | PTGS1HSD17B10TDP1CMA1 | |
| Moxalactam SCHEMBL194013 | 0.99 | PTGS1 (1.00) | PTGS1HSD17B10TDP1CMA1 | |
| Moxalactam SCHEMBL14196602 | 0.99 | PTGS1 (1.00) | PTGS1HSD17B10TDP1CMA1 | |
| Moxalactam SCHEMBL194012 | 0.99 | PTGS1 (1.00) | PTGS1HSD17B10TDP1CMA1 | |
| Moxalactam SCHEMBL49016 | 0.99 | PTGS1 (1.00) | PTGS1HSD17B10TDP1CMA1 | |
| Moxalactam SCHEMBL49017 | 0.99 | PTGS1 (1.00) | PTGS1HSD17B10TDP1CMA1 | |
| Moxalactam SCHEMBL3382938 | 0.92 | PTGS1 (0.87) | PTGS1HSD17B10TDP1CMA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4393512-B1 | COMPOSITION FOR PHARMACEUTICAL TABLET, PHARMACEUTICAL TABLET USING THE SAME, AND MANUFACTURING METHOD THEREOF | MITSUBISHI CHEM CORP (JP) | 2025-10-01 | — | — | EP | disclosed |
| EP-4393512-A1 | COMPOSITION FOR MEDICINAL TABLET, MEDICINAL TABLET OBTAINED USING SAME, AND PRODUCTION METHOD THEREFOR | Mitsubishi Chemical Corporation (JP) | 2024-07-03 | — | — | EP | disclosed |
| US-20240173260-A1 | COMPOSITION FOR PHARMACEUTICAL TABLET, PHARMACEUTICAL TABLET USING THE SAME, AND MANUFACTURING METHOD THEREOF | MITSUBISHI CHEMICAL CORPORATION (JP) | 2024-05-30 | — | — | US | disclosed |
| EP-3607084-B1 | A METHOD FOR TESTING ANTIMICROBIAL SUSCEPTIBILITY | UNIV WESTERN AUSTRALIA (AU) | 2024-05-01 | — | — | EP | disclosed |
| EP-4316469-A1 | COMPOSITION FOR SUSTAINED-RELEASE SOLID PREPARATION, SUSTAINED-RELEASE TABLET USING SAME AND MANUFACTURE METHOD THEREOF | Mitsubishi Chemical Corporation (JP) | 2024-02-07 | — | — | EP | disclosed |
| US-20240000712-A1 | COMPOSITION FOR SUSTAINED-RELEASE SOLID DOSAGE FORM, SUSTAINED-RELEASE TABLET USING THE SAME, AND MANUFACTURING METHOD THEREOF | MITSUBISHI CHEMICAL CORPORATION (JP) | 2024-01-04 | — | — | US | disclosed |
| CN-117069739-A | Preparation method of high-purity sodium cefuroxime axetil | 山西千岫制药有限公司 | 2023-11-17 | — | — | CN | disclosed |
| CN-116296745-A | Method for detecting impurities in sodium cefuroxime axetil freeze-dried powder for injection | 杭州沐源生物医药科技有限公司 | 2023-06-23 | — | — | CN | disclosed |
| WO-2022202138-A1 | COMPOSITION FOR SUSTAINED-RELEASE SOLID PREPARATION, SUSTAINED-RELEASE TABLET USING SAME AND MANUFACTURE METHOD THEREOF | 三菱ケミカル株式会社 | 2022-09-29 | — | — | WO | disclosed |
| CN-113387960-B | Refining method of latamoxef sodium intermediate | 海南海灵化学制药有限公司 | 2022-04-22 | — | — | CN | disclosed |
| US-20210292807-A1 | METHOD FOR TESTING ANTIMICROBIAL SUSCEPTIBILITY | THE UNIVERSITY OF WESTERN AUSTRALIA (AU) | 2021-09-23 | — | — | US | disclosed |
| CN-113387960-A | Refining method of latamoxef sodium intermediate | 海南海灵化学制药有限公司 | 2021-09-14 | — | — | CN | disclosed |
| CN-109485659-B | Process for preparing 7 alpha-alkoxyoxycephalosporane intermediates | 东都股份有限公司 | 2021-09-10 | — | — | CN | disclosed |
| EP-3607084-A1 | A METHOD FOR TESTING ANTIMICROBIAL SUSCEPTIBILITY | The University Of Western Australia (AU) | 2020-02-12 | — | — | EP | disclosed |
| WO-2018184073-A1 | A METHOD FOR TESTING ANTIMICROBIAL SUSCEPTIBILITY | THE UNIVERSITY OF WESTERN AUSTRALIA (AU) | 2018-10-11 | — | — | WO | disclosed |
| EP-0256713-A2 | Therapeutic human antipseudomonas aeruginosa antibodies | MERCK & CO. INC. (US) | 1988-02-24 | — | — | EP | disclosed |